

Glatiramer Acetate (Copaxone, Glatopa)

Disclaimer

Clinical guidelines are developed and adopted to establish evidence-based clinical criteria for utilization management decisions. Clinical guidelines are applicable according to policy and plan type. The Plan may delegate utilization management decisions of certain services to third parties who may develop and adopt their own clinical criteria.

Coverage of services is subject to the terms, conditions, and limitations of a member's policy, as well as applicable state and federal law. Clinical guidelines are also subject to in-force criteria such as the Centers for Medicare & Medicaid Services (CMS) national coverage determination (NCD) or local coverage determination (LCD) for Medicare Advantage plans. Please refer to the member's policy documents (e.g., Certificate/Evidence of Coverage, Schedule of Benefits, Plan Formulary) or contact the Plan to confirm coverage.

Summary

Multiple sclerosis (MS) is a chronic, inflammatory, demyelinating disease of the central nervous system. It typically presents in young adults (generally diagnosed before 50 years of age) with symptoms such as vision problems, muscle weakness, numbness, and difficulty with balance and coordination. The most common form is relapsing-remitting MS (occurring in about 85% of patients), characterized by acute attacks followed by periods of remission. Treatment goals include reducing relapses, slowing disability progression, and managing symptoms. Disease-modifying therapies are the primary treatment approach and include injectable medications (e.g., interferons, glatiramer acetate), oral medications (e.g., dimethyl fumarate, fingolimod, teriflunomide, etc.), and infusion therapies (e.g., natalizumab, ocrelizumab).

Glatiramer acetate is a medication prescribed for adults with various relapsing forms of multiple sclerosis (MS). These forms include clinically isolated syndrome, relapsing-remitting MS, and active secondary progressive MS. Clinical studies have demonstrated that glatiramer acetate can decrease the frequency of relapses in patients with relapsing-remitting MS. Additionally, for individuals who have experienced a single clinical episode and show MRI findings suggestive of MS, this drug has been found to lower the likelihood of the condition progressing to definitive MS. Glatiramer acetate is administered subcutaneously (SUBQ) using a prefilled syringe or a compatible injection device.

Definitions

"Clinically isolated syndrome" refers to a first episode of neurologic symptoms lasting at least 24 hours caused by inflammation or demyelination in the central nervous system.

"Disease-modifying therapy" is a medication that modifies the course of MS by reducing relapses and slowing disability progression.

"Multiple sclerosis" is a chronic autoimmune disease of the central nervous system characterized by inflammation, demyelination, and neurodegeneration.

"Primary progressive MS" refers to worsening neurologic function from the onset of symptoms, without early relapses or remissions.

"Relapse" is defined as the appearance of new symptoms or the worsening of existing symptoms lasting at least 24 hours in the absence of fever or infection.

"Relapsing-remitting MS" refers to a disease course characterized by clearly defined attacks of new or increasing neurologic symptoms followed by periods of partial or complete recovery.

"Secondary progressive MS" is a disease course following relapsing-remitting MS that is characterized by a progressive worsening of neurologic function over time with or without relapses.

Medical Necessity Criteria for Initial Authorization

The Plan considers Glatiramer Acetate (Copaxone, Glatopa) when recent (within the last 3 months) clinical chart documentation provided indicates the member meets ALL of the following:

1. The medication is prescribed by or in consultation with a neurologist or physician who specializes in the treatment of multiple sclerosis; *AND*
2. Is 18 years of age or older; *AND*
3. Has ONE of the following forms of multiple sclerosis:
 - a. relapsing-remitting (RRMS); *or*
 - b. active secondary progressive disease (SPMS); *or*
 - c. clinically isolated syndrome (CIS); *AND*
4. For generic glatiramer products (i.e., glatiramer acetate, Glatopa) - the member is unable to use, or has tried and failed Copaxone (glatiramer acetate); *AND*
5. Glatiramer Acetate will be used as monotherapy for multiple sclerosis (i.e., member is not using and will not use other disease-modifying MS therapies while on Glatiramer Acetate); *AND*
6. Glatiramer Acetate is being prescribed within the manufacturer's published dosing guidelines or falls within dosing guidelines found in a compendia of current literature.
 - o *The recommended dose is either:*

- i. 20 mg/mL administered subcutaneously once daily; or
 - 1. 20 mg/mL: 30 syringes per 30 days
- ii. 40 mg/mL administered subcutaneously three times per week at least 48 hours apart.
 - 1. 40 mg/mL: 12 syringes per 28 days

If the above prior authorization criteria are met, the requested product will be authorized for up to 12-months.

Medical Necessity Criteria for Reauthorization

Reauthorization for up to 12 months will be granted if the member has recent (within the last 6-months) clinical documentation showing BOTH of the following:

1. The requested medication is prescribed by or in consultation with a neurologist or a physician who specializes in the treatment of multiple sclerosis; **AND**
2. The member has experienced at least **ONE** of the following:
 - a. Improvement in at least **ONE** objective measure, such as:
 - i. Reduced disease activity on MRI; *and/or*
 - ii. Improved or stable disability scores; *and/or*
 - iii. Reduced relapse rate; *and/or*
 - iv. Improved fatigue or walking assessments; **AND/OR**
 - b. The member has shown stabilization or improvement in at least **ONE** MS symptom, such as:
 - i. Motor function; *and/or*
 - ii. Fatigue; *and/or*
 - iii. Vision; *and/or*
 - iv. Bowel/bladder function; *and/or*
 - v. Spasticity; *and/or*
 - vi. Walking/gait; *and/or*
 - vii. Pain/numbness/tingling.

Experimental or Investigational / Not Medically Necessary

Glatiramer Acetate (Copaxone, Glatopa) for any other indication or use is considered not medically necessary by the Plan, as it is deemed to be experimental, investigational, or unproven. Non-covered indications include, but are not limited to, the following:

- Use for the treatment of primary progressive multiple sclerosis.
- Use in combination with other disease-modifying therapies for multiple sclerosis.
- Use in members under 18 years of age.
- Use for indications other than FDA-approved relapsing forms of multiple sclerosis.

References

1. Bainbridge JL, Miravalle A, Wong PS. Multiple Sclerosis. In DiPiro JT, Yee GC, Posey LM, et al, eds. *Pharmacotherapy: A Pathophysiologic Approach*. 11th ed. New York, NY: McGraw-Hill; 2019.
2. Bornstein MB, Miller A, Slagle S, et al. A pilot trial of Cop 1 in exacerbating-relapsing multiple sclerosis. *N Engl J Med*. 1987;317(7):408-414. doi:10.1056/NEJM198708133170703.
3. Comi G, Filippi M, Wolinsky JS; and the European/Canadian Glatiramer Acetate Study Group. European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis. *Ann Neurol*. 2001;49(3):290-297. <https://doi.org/10.1002/ana.64>
4. Comi G, Martinelli V, Rodegher M, et al. Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial. *Lancet*. 2009 Oct 31;374(9700):1503-11. doi: 10.1016/S0140-6736(09)61259-9. Epub 2009 Oct 6. Erratum in: *Lancet*. 2010 Apr 24;375(9724):1436.
5. Copaxone (glatiramer acetate) [prescribing information]. Parsippany, NJ: Teva Neuroscience Inc; November 2023.
6. Ford CC, Cohen JA, Goodman AD, et al. Early versus delayed treatment with glatiramer acetate: Analysis of up to 27 years of continuous follow-up in a US open-label extension study. *Mult Scler*. 2022 Oct;28(11):1729-1743. doi: 10.1177/13524585221094239. Epub 2022 Jun 29.
7. Glatopa (glatiramer acetate) [prescribing information]. Princeton, NJ: Sandoz Inc; March 2023.
8. Hauser, S., & Cree, B. (2020). Treatment of Multiple Sclerosis: A Review.. *The American journal of medicine*. <https://doi.org/10.1016/j.amjmed.2020.05.049>.
9. Johnson KP, Brooks BR, Cohen JA, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-relapsing multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. *Neurology*. 1995 Jul;45(7):1268-76. doi: 10.1212/wnl.45.7.1268.
10. Khan O, Rieckmann P, Boyko A, Selmaj K, Zivadinov R; GALA Study Group. Three times weekly glatiramer acetate in relapsing-relapsing multiple sclerosis. *Ann Neurol*. 2013 Jun;73(6):705-13. doi: 10.1002/ana.23938. Epub 2013 Jun 28.
11. Li H, Hu F, Zhang Y, Li K. Comparative efficacy and acceptability of disease-modifying therapies in patients with relapsing-relapsing multiple sclerosis: a systematic review and network meta-analysis. *J Neurol*. 2020 Dec;267(12):3489-3498. doi: 10.1007/s00415-019-09395-w. Epub 2019 May 25.
12. McGinley MP, Goldschmidt CH, Rae-Grant AD. Diagnosis and Treatment of Multiple Sclerosis: A Review. *JAMA*. 2021;325(8):765-779. doi:10.1001/jama.2020.26858
13. Multiple Sclerosis Society of Canada. Disease-modifying therapies. <https://mssociety.ca/managing-ms/treatments/medications/disease-modifying-therapies-dmts>.
14. National MS Society. Disease-modifying therapies for MS (updated March 2022). Available from National MS Society website: <https://nms2cdn.azureedge.net/cmssite/nationalmssociety/media/msnationalfiles/brochures/brochure-the-ms-disease-modifying-medications.pdf>.
15. Rae-Grant A, Day GS, Marrie RA, et al. Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. *Neurology*. 2018;90(17):777-788.
16. Reich DS, Lucchinetti CF, Calabresi PA. 2018. Multiple sclerosis. *New England Journal of Medicine* 378(2):169-180

17. The use of disease-modifying therapies in multiple sclerosis: principles and current evidence summary. Multiple Sclerosis Coalition. Available from the National MS Society Website: <https://www.nationalmssociety.org/>.
18. Tramacere I, Del Giovane C, Salanti G, et al. Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis. *Cochrane Database Syst Rev* 2015;9:CD011381.
19. Yang, J., Rempe, T., Whitmire, N., Dunn-Pirio, A., & Graves, J. (2022). Therapeutic Advances in Multiple Sclerosis. *Frontiers in Neurology*, 13. <https://doi.org/10.3389/fneur.2022.824926>.

Clinical Guideline Revision / History Information

Original Date: 06/27/2024

Reviewed/Revised: 12/19/2024, 10/01/2025